Figures and data in Effect of cancer on outcome of COVID-19 patients: a systematic review and meta-analysis of studies of unvaccinated patients

Version of Record: March 25, 2022
Accepted Manuscript: February 16, 2022

Download
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
- Article PDF
- Figures PDF
Open citations (links to open the citations from this article in various online reference manager services)
- Mendeley
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Giulia Di Felice

Giovanni Visci

Federica Teglia

Marco Angelini

Paolo Boffetta

(2022)
Effect of cancer on outcome of COVID-19 patients: a systematic review and meta-analysis of studies of unvaccinated patients

eLife 11:e74634.

https://doi.org/10.7554/eLife.74634
- Download BibTeX
- Download .RIS
Cite
Share
CommentOpen annotations (there are currently 0 annotations on this page).

Figures
Tables
Additional files

7 figures, 2 tables and 3 additional files

Figures

Figure 1

Download asset Open asset

Flowchart for the identification of articles for the meta-analyses (PRISMA).

Figure 2

Download asset Open asset

Forest plot – all types of cancer – outcome 1.

Figure 3

Download asset Open asset

Forest plot – all types of cancer – outcome 2.

Figure 4

Download asset Open asset

Forest plot – all types of cancer – outcome 3 or 4.

Figure 5

Download asset Open asset

Funnel plot of Egger’s test to assess publication bias – all types of cancer – outcome 1.

Figure 6

Download asset Open asset

Forest plot – all types of cancer – outcome 1 – reported versus calculated OR.

Figure 7 with 1 supplement

Download asset Open asset

Forest plot – hematological neoplasms – outcome 1.

Figure 7—figure supplement 1

Download asset Open asset

Forest plot – hematological neoplasms – outcome 2, 3, or 4.

Tables

Table 1

Selected characteristics of studies included in the meta-analysis – all cancers.

References	Country	N patients	N outcomes	Quality score	Comparison	Outcome	RR/OR*	95% CI
Dai et al., 2020	China	641	105	9.25	Internal	Mortality	2.34	1.15–4.77
						ICU	2.84	1.59–5.08
						Severity	2.79	1.75–4.44
Haase et al., 2021	Denmark	323	15	11.5	Internal	Mortality	3.18	1.66–6.09
Meng et al., 2020	China	436	109	9.5	Internal	Mortality	2.98†	1.76–5.05
Sun et al., 2020	USA	323	67	10.5	Internal	Mortality	5.67†	1.49–21.58
						ICU	1.91†	0.90–4.06
						Hospitalization	2.16†	1.12–4.17
Nogueira et al., 2020	Portugal	20,293	611	9.25	Internal	Mortality	1.48	1.07–2.05
Zandkarimi et al., 2020	Iran	1831	32	6.5	Internal	Mortality	3.57	1.82–7.02
Zhao et al., 2020	China	539	23	6.5	Internal	Mortality	3.23	1.39–7.51
Harrison et al., 2020	USA	31,461	1966	9.75	Internal	Mortality	0.87†	0.72–1.09
Gupta et al., 2020	USA	2215	112	7.5	Internal	Mortality	2.20	1.50–3.22
Ganatra et al., 2020	USA	2476	195	9.25	Internal	Mortality	3.53	2.95–4.23
						Severity	3.75	3.17–4.44
						Hospitalization	2.78	2.37–3.26
Westblade et al., 2020	USA	2294	100	8.5	Internal	Mortality	1.29	1.04–1.61
						Severity	0.76	0.57–1.01
Wang et al., 2020	USA	16,570	1200	11	Internal	Mortality	3.20	2.89–3.55
						Hospitalization	2.85	2.63–3.09
Cherri et al., 2020	Italy	2039	53	11	Internal	Mortality	2.22†	1.25–3.94
Görgülü and Duyan, 2020	Turkey	483	75	11	Internal	Mortality	1.81†	0.88–3.72
						ICU	2.14	1.26–3.63
Jiménez et al., 2020	Spain	1549	103	9.75	Internal	Mortality	4.29†	2.40–7.67
Thompson et al., 2020	UK	470	87	10	Internal	Mortality	2.20†	1.27–3.81
Li et al., 2020	China	1859	65	9	External	Mortality	1.59†	0.94–2.68
Shoumariyeh et al., 2020	Germany	78	39	8.5	External	Mortality	1.01	0.41–2.49
						Severity	1.15	0.61–2.17
Mehta et al., 2020	USA	1308	218	8.5	External	Mortality	2.38	1.69–3.35
Rogado et al., 2020	Spain	42,495	45	8	External	Mortality	4.82	2.67–8.71
Brar et al., 2020	USA	585	117	9.5	External	Mortality	0.98	0.58–1.66
						Severity	0.80	0.57–1.13
Zhang et al., 2020b	China	217	112	9.5	External	Mortality	4.83	2.87–8.12
						ICU	2.60	1.87–3.62
						Severity	1.43	1.09–1.87
Sorouri et al., 2020	Iran	159	53	10	External	Mortality	3.27†	0.93–11.55
						ICU	1.52†	0.56–4.12
Lunski et al., 2021	USA	5145	312	9.5	External	Mortality	2.03†	1.44–2.87
Atalla et al., 2021	USA	339	27	10.5	Internal	Hospitalization	3.34	1.81–6.16
Cheng et al., 2020	China	1476	29	6	Internal	Severity	2.14	0.97–4.73
Song et al., 2021	China	961	21	7	Internal	Severity	2.77	1.16–6.62
Liang et al., 2020	China	1590	18	8.75	Internal	Severity	4.07†	1.23–13.45
Bauer et al., 2021	USA	1449	108	8.5	Internal	Severity	1.72†	1.11–2.67
Tian et al., 2020	China	751	232	9	External	Severity	3.75	2.71–5.19

*

Results derived from data reported in the publication are in italics.
†

Risk estimates derived from multivariate analysis.
RR: Relative Risk; OR: Odds Ratio; CI: Confidence interval; ICU: Intensive Care Unit.

Table 2

Selected characteristics of studies included in the meta-analysis – hematological tumors.

Author – Year	Country	Sample size (n)	Cancer (n)O number of cancer (%)	Quality assessment (CASP)	Comparison	Outcome	RR/OR*	IC
Dai et al., 2020	China	641	9	9.25	Internal	Mortality	9.07	2.16–38.13
Haase et al., 2021	Denmark	323	13	11.5	Internal	Mortality	1.83	0.85–3.93
Meng et al., 2020	China	327	16	9.5	Internal	Mortality	2.83†	0.96–8.32
Yigenoglu et al., 2021	Turkey	1480	740	10.5	External	Mortality	2.20	1.93–2.50
Shah et al., 2020	UK	1183	68	9.75	External	Mortality	1.74†	1.12–2.71
Sanchez-Pina et al., 2020	Spain	92	39	10.25	External	Mortality	6.65†	1.87–23.67
Passamonti et al., 2020	Italy		536	11	External	Mortality	2.04†	1.77–2.35
Cattaneo et al., 2020	Italy	204	102	9	External	Mortality	2.10	1.14–3.85

*

italics characters when calculated manually.
†

Risk estimates derived from multivariate analysis.
CASP: Critical Appraisal Skills Programme; RR: Relative Risk; OR: Odds Ratio; IC: Interval Confidence; ICU: Intensive Care Unit.